As of January 22, 2025, Mainz Biomed (MYNZ) has a market cap of $9.997 million USD. According to our data, Mainz Biomed is ranked No.8859 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $10.00 M |
4.17%
|
Dec 31, 2024 | $9.60 M |
272.41%
|
Dec 29, 2023 | $2.58 M |
-83.66%
|
Dec 30, 2022 | $15.77 M |
-31.67%
|
Dec 31, 2021 | $23.08 M |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Exact Sciences
EXAS
|
$10.14 B |
0.000 M
|
USA
|
Guardant Health
GH
|
$5.83 B |
0.000 M
|
USA
|
Natera
NTRA
|
$22.70 B |
-0.001 M
|
USA
|
Fulgent Genetics
FLGT
|
$0.52 B |
-0.000 M
|
USA
|
NeoGenomics
NEO
|
$1.86 B |
0.000 M
|
USA
|
Myriad Genetics
MYGN
|
$1.12 B |
-0.000 M
|
USA
|
Adaptive Biotechnologies
ADPT
|
$1.18 B |
0.000 M
|
USA
|
Illumina
ILMN
|
$22.26 B |
0.000 M
|
USA
|
QuidelOrtho
QDEL
|
$2.99 B |
-0.000 M
|
USA
|
Hologic
HOLX
|
$16.07 B |
-0.000 M
|
USA
|
Qiagen
QGEN
|
$10.50 B |
0.000 M
|
Netherlands
|
Becton Dickinson
BDX
|
$69.00 B |
-0.002 M
|
USA
|
Market Cap | = | MYNZ Stock Price | * | MYNZ Shares Outstanding |
= | $4.50 | * | 2.22 M | |
= | $10.00 M |